IF YOU MEET ANY OF THESE INDICATIONS, PLEASE CONTACT US AT
strong>800 390 390
CZECANCA
The most comprehensive cancer risk assessment
The CZECANCA panel (CZEch CAncer paNel for Clinical Application) is a detailed genetic analysis for the investigation of cancer predisposition. It examines a broad spectrum of hereditary cancers, currently including 226 target genes, which are constantly updated. The CZECANCA panel was developed by the group of doc. MUDr. Kleibl from the Institute of Biochemistry and Experimental Oncology, 1st Medical Faculty of Charles University in Prague. The results of the tests allow mapping of risk mutations in the Czech population and give you an answer whether you are at high risk of developing cancer.
IN WHICH SITUATIONS IT IS APPROPRIATE TO TAKE THE TEST
EARLY PREVENTION
You want to prevent potential risks in time.
PERSONAL MEDICAL HISTORY
History of cancer in the past.
FAMILY MEDICAL HISTORY
Family history of cancer.
POSITIVE DIAGNOSIS
Before choosing an appropriate treatment in case of illness.
WEIGHT LOSS
You lose weight and suffer from fatigue.
PUBLIC HEALTH INSURANCE COVERS THE TEST IN THE FOLLOWING SITUATIONS
When testing for breast and ovarian cancer is covered by public health insurance:
Sporadic forms:
-
Ovarian, fallopian tube, and primary peritoneal cancer regardless of age.
-
Triple negative/medullary breast cancer at any age.
-
Unilateral breast cancer in a woman under 45 years of age (under 50 years if there is no known family history).
-
Two separate primary breast cancers, the first by age 50 or both by age 60 (bilateral or ipsilateral, synchronous or metachronous).
-
Synchronous onset of breast and pancreatic cancer at any age.
-
A man with breast cancer at any age.
Familial occurrence:
-
At least three female relatives with breast cancer of any age (including the patient).
-
2 female relatives with breast cancer, at least one under 50 or both under 60.
-
A female breast cancer patient of any age with a direct relative with ovarian cancer, triple negative/medullary breast cancer, pancreatic cancer, male breast cancer, high-grade (Gleason score ≥ 7) or primary metastatic prostate cancer.
-
Patient with lobular breast cancer and a personal or family history of diffuse gastric cancer.
If the relative who was diagnosed with cancer is no longer living, testing according to the above criteria is available for first-degree relatives, and for second-degree relatives with a family history on the father's side.
Indications for prostate cancer testing:
-
Incidence of ≥ 2 cases of prostate cancer in personal or family history, with at least one at age ≤ 55 years.
-
≥ 3 cases of prostate cancer in close relatives, death due to prostate cancer.
-
Prostate cancer (Gleason score ≥ 7) or primary metastatic prostate cancer and ≥ 1 case of breast cancer, ovarian cancer, endometrial cancer, bowel or stomach cancer, kidney carcinoma, malignant melanoma, pancreatic cancer, bladder cancer, gallbladder cancer.
If you have a personal and/or family history of other cancers (colon or small bowel cancer, uterine cancer, kidney cancer, etc.), genetic analysis may also be covered by public health insurance after a risk assessment by a clinical geneticist.
Schedule a genetic consultation.
DETAILED INFORMATION
Malignant neoplastic diseases are the second most common cause of death. In most cases, they arise as a result of DNA defects during life, but in rare cases they are caused by hereditary dispositions. And it is this group of cancers that the CZECANCA testing focuses on. It can detect hereditary mutations responsible for specific cancers.
The purpose of the test is to confirm or exclude the risk of hereditary cancer predisposition in a patient or a healthy relative. Once a patient is diagnosed, the identification of the congenital predisposition allows for setting up treatment and follow-up at specialised centres. The genetic findings are explained to the patient in detail and in a clear manner during the consultation. For people with a risk mutation, it is possible to perform preimplementation diagnostics as part of IVF and to prevent the transmission of the mutation to the next generation by selecting a suitable embryo.
Our laboratory is internationally accredited for cancer testing using massively parallel sequencing with the CZECANCA panel. We use state-of-the-art CE-IVD software and bioinformatics procedures for data analysis. We regularly participate in inter-laboratory audits and, thanks to our connection with the CZECANCA expert consortium, update the most accurate diagnostic procedures for cancer predisposition.
You will receive the result within 1– 2 months.
HOW THE TEST WORKS AND WHAT YOU CAN EXPECT
After ordering the test, you will receive an email with detailed information. A DNA sample is most often obtained through an oral swab or blood sample. You can perform the oral swab yourself in the comfort of your own home using a collection kit, which will be sent to you by mail together with instructions and other documents. You can have your blood drawn at your local physician's office or at our outpatient clinic. The result of the analysis will be sent to you by e-mail or by post as agreed. In case of a positive result, we will arrange a consultation with a clinical geneticist who will explain everything and recommend appropriate measures.
1.
Ordering
Choose a specific test or make an appointment for a genetic consultation.2.
Sampling
A sample of your DNA is most often obtained through an oral swab or blood sample.3.
Analysis
Our team of experienced professionals will analyse the sample using the latest methods and technologies.4.
RESULT
After the test has been evaluated, you will receive a detailed and easy-to-understand laboratory report, or a consultation with a clinical geneticist will be recommended.Frequently Asked Questions
The time required for the laboratory examination (sample analysis) and the delivery date of the result vary according to the type and complexity of the examination. Usually it is in the order of weeks, for complex tests up to several months. The delivery date of the result is indicated in the details of each test on our website. In urgent situations, e.g. for a woman with a newly diagnosed breast or ovarian tumour before surgery, the oncopanel cancer test is performed in STATIM mode and the result is available within 3-4 weeks, whereas in normal mode it takes up to 6 months.
Health insurance always covers genetic consultations recommended by the attending physician (usually a general practitioner, paediatrician, oncologist, gynaecologist or other specialist). During the consultation, a clinical geneticist will assess whether the indication criteria for testing for the predisposition genes are met; if so, the entire genetic test, including laboratory analysis of the sample and subsequent consultation with the geneticist/doctor, is covered by health insurance. If the criteria for the genetic testing are not met, the patient can pay for the selected/recommended test as a self-payment.
After making an appointment, you will come to our office where you will first fill out a personal and family history questionnaire, or you can download it from here on our website and fill it out in advance, in the comfort of your own home. Remember to bring it with you afterwards. This is followed by a consultation with a doctor who will compile your three-generation family tree and decide on the indication for laboratory genetic testing. We also recommend that you bring medical reports from recent important examinations.
Recommendation - a referral from the doctor who recommended the genetic consultation. Alternatively, a completed genetic family and personal history questionnaire, which can be downloaded here. However, the questionnaire can also be completed after you arrive at our office. Medical reports from previous examinations related to the requested genetic test. It is not necessary to be fasting for the genetic examination, so you can easily make an appointment in the afternoon.
It has been reported that approximately 5-10% of cancers are caused by inborn changes in certain genes. One of the main goals of predictive genetic testing is the early identification of people at risk. If risk predispositions (gene mutations) are detected, preventive follow-up at specialised centres is recommended, where possible cancers are detected early and the chances of successful treatment are increased. In the case of high-risk mutations, preventive surgery may be recommended to make the risk of cancer in a given organ virtually impossible (for example, removal of the breast glands or removal of the uterus and ovary in BRCA1 or BRCA2 mutation carriers).
If your first-degree relative (parents, siblings, children) develops colon cancer before the age of 45, your risk of developing this cancer is 5 times higher. If you have three first-degree relatives, your risk can be as high as 50%. In families with a history of recurrent bowel cancer or with a history of bowel cancer at a young age, it could be hereditary cancer syndrome (Lynch syndrome). In such cases, genetic consultation is recommended.